Having trouble viewing this email? View in your browser.
ESCMID Logo

30 October 2018
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

ICOHAR registration and abstract submission now open

The International Conference on One Health Antimicrobial Resistance (ICOHAR), supported by ESCMID and ESGVM, is taking place immediately after ECCMID in Utrecht, Netherlands.

Abstract submission for this conference is also now open.

See the program and register here!

› Read more
Open Calls | Applications

ECCMID Abstract submissions are open!

Submission of abstracts for ECCMID 2019 are open, and will close on 28 November 2018.

› Read more

New EUCAST definitions of S, I and R

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has decided to change the definitions of S, I and R. The change, which will take effect 1st of January 2019, has been prepared for more than 3 years and was preceded by several international open consultations. In the new definitions, the S and I categories now both represent susceptible, the difference between the  level of agent exposure needed at the site of infection, where I represents "Susceptible, increased exposure". Through a series of activities, EUCAST will now now help explain the change to colleagues and other health care staff. One such activity is the publication of a power point presentation which can be used to inform clinical colleagues and laboratory staff. The presentation can be downloaded from the EUCAST webpage.

› Read more
 

Report of Antimicrobial Resistance: From Bench to Practice, Havana, Cuba

Registration grant recipient Piotr Kochan has published an excellent summary of the recent ESCMID conference in Havana, Cuba.

Read more about Piotr’s experience here.

› Read more
 

International consensus document for the optimal use of the polymyxins: open for public consultation

The draft version of the international consensus document for the optimal use of polymyxins has now entered into the public consultation phase. This joint project came together through the concerted efforts of the American College of Clinical Pharmacy (ACCP), the Infectious Diseases Society of America (IDSA), the International Society for Anti-infective Pharmacology (ISAP), the Society of Infectious Diseases Pharmacists (SIDP) and ESCMID.

Those of you wishing to comment on the manuscript may write to the ESCMID Publications and Medical Guidelines Manager to request the (confidential) draft of the manuscript along with the comments form for listing feedback. We are happy to receive your feedback and comments on the manuscript until 26 November 2018. Please be aware that your comments and the authors’ responses to the comments will be made available online once the guideline is published.

› Read more
 

CMI highlight: re Treatment HIV-1 Drug Resistance In Transmission Clusters Of The Cologne-Bonn Region, Germany

Previous reports in Germany demonstrated transmitted HIV-1 drug resistance mutations (DRM) in 11% of newly diagnosed individuals. In this work, Stecher and colleagues sought to understand the molecular epidemiology of HIV DRM transmission in the Cologne-Bonn region (Germany), which has one of the highest rates of new HIV diagnoses in Western Europe (13.7 per 100,000 habitants). Screening of 714 HIV-1 ART na´ve infected individuals revealed a prevalence of any DRM at the time of diagnosis of 17.2% (123/714 participants). Genetic transmission network analyses showed comparable frequencies of DRM in clustering vs. not clustering individuals [17.1% (85/497) versus 17.5 % (38/217)]. The observed rate of DRMs in the region was higher than in previous reports 10.8% (87/809) (<0.001), revealing the need to reduce onward transmission in this area. Finally, genetically linked individuals harboring shared DRMs were more likely to live in suburban areas (24/38) than in central Cologne (1/38) (p<0.001). The results of this study indicate an exceptionally high rate of DRMs. Network analysis elucidated frequent cases of shared DRMs among genetically linked individuals, revealing the potential spread of DRMs and the need to prevent onward transmission of DRM in the Cologne-Bonn area.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.